Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Fairness for Beneficiaries Act of 2013
Client: TRAUMA CENTER ASSOCIATION OF AMERICA · Firm: HOLLAND & KNIGHT LLP
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparedness Act; development of field EMS legislation HR 3144 and primary federal agency.
Field EMS Quality, Innovation, and Cost Effectiveness Improvements Act of 2013
Client: TRAUMA CENTER ASSOCIATION OF AMERICA · Firm: HOLLAND & KNIGHT LLP
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
NATIONAL FISHERIES INSTITUTE via HOLLAND & KNIGHT LLP
2013 · second_quarter · Q2
Implementation of The Food, Conservation & Energy Act (Public Law No: 110-246); S.954, the Agriculture Reform, Food and Jobs Act of 2013; H.R. 1947, the Federal Agriculture Reform and Risk Management Act of 2013; importer bond requirements.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2013 · second_quarter · Q2
Source: Senate LDA
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; development of field EMS legislation (H.R. 809) that would establish a primary federal agency; development of new reimbursement model for trauma centers.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for creation of national strategy for regenerative medicine. Met with OSTP officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation. Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 and FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for creation of federal coordinating entity for regenerative medicine. Met with NIH officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied for FDA and NIH appropriation increase to prevent sequestration of funds.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in HR 5651 & S. 3187 Patient Centered Outcomes Research Institute (PCORI). Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 the FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products. Drafted and submitted comments on proposed "methodology report" regarding comparative effectiveness research from the Patient Centered Outcome Research Institute.
Field EMS Quality, Innovation, and Cost Effectiveness Improvements Act of 2011
Client: TRAUMA CENTER ASSOCIATION OF AMERICA · Firm: HOLLAND & KNIGHT LLP
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Field EMS Quality, Innovation, and Cost Effectiveness Improvements Act of 2011
Client: TRAUMA CENTER ASSOCIATION OF AMERICA · Firm: HOLLAND & KNIGHT LLP
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Food and Drug Administration Reform Act of 2012
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for creation of national strategy for regenerative medicine. Met with OSTP officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation. Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 and FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products.
Food and Drug Administration Reform Act of 2012
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in HR 5651 & S. 3187 Patient Centered Outcomes Research Institute (PCORI). Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 the FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products. Drafted and submitted comments on proposed "methodology report" regarding comparative effectiveness research from the Patient Centered Outcome Research Institute.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with FDA officials about same. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Regenerative Medicine Promotion Act of 2011
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Regenerative Medicine Promotion Act of 2010
Client: ALLIANCE FOR REGENERATIVE MEDICINE · Firm: HOLLAND & KNIGHT LLP
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Lobby in support of HR 6173. Advocate for new/modified regulations re: aprroval of regenerative medicine products. The Regenerative Medicine Promotion Act of 2010. Met with NIST to explore collaborations re: product standards
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; development of field EMS legislation (H.R. 809) that would establish a primary federal agency; development of new reimbursement model for trauma centers.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2013 · second_quarter · Q2
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of legislation that will establish the national strategy, including a GAO report and federal policy coordination.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2013 · first_quarter · Q1
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparedness Act; development of field EMS legislation HR 3144 and primary federal agency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
NATIONAL FISHERIES INSTITUTE via HOLLAND & KNIGHT LLP
2013 · first_quarter · Q1
Implementation of The Food, Conservation & Energy Act (Public Law No: 110-246); The 2012 Farm Bill; importer bond requirements.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2013 · first_quarter · Q1
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of legislation that will establish the national strategy, including a GAO report and federal policy coordination.
Filing targets: HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE
NATIONAL FISHERIES INSTITUTE via HOLLAND & KNIGHT LLP
2012 · fourth_quarter · Q4
Implementation of The Food, Conservation & Energy Act (Public Law No: 110-246); The 2012 Farm Bill; importer bond requirements.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, U.S. Trade Representative (USTR), White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2012 · fourth_quarter · Q4
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied for FDA and NIH appropriation increase to prevent sequestration of funds.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
NATIONAL FISHERIES INSTITUTE via HOLLAND & KNIGHT LLP
2012 · third_quarter · Q3
Implementation of The Food, Conservation & Energy Act (Public Law No: 110-246); The 2012 Farm Bill; importer bond requirements.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2012 · third_quarter · Q3
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2012 · third_quarter · Q3
Advocate for creation of national strategy for regenerative medicine. Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in HR 5651 & S. 3187 Patient Centered Outcomes Research Institute (PCORI). Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 the FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products. Drafted and submitted comments on proposed "methodology report" regarding comparative effectiveness research from the Patient Centered Outcome Research Institute.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
TRAUMA CENTER ASSOCIATION OF AMERICA via HOLLAND & KNIGHT LLP
2012 · second_quarter · Q2
Implementation of health reform law affecting trauma centers PL 111-148; 111-152; support appropriations for trauma provisions in the Public Health Service Act pursuant to Labor/HHS appropriations legislation and discretionary funding within the Department of HHS; recognition of trauma issues in Pandemic and All Hazards Preparadness Act; development of field EMS legislation HR 3144 and primary federal agency.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2012 · second_quarter · Q2
Advocate for creation of national strategy for regenerative medicine. Met with OSTP officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation. Lobbied for FDA appropriation increase. FDA appropriations eventually included in HR 2112 and S. 2375 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. Lobbied for accelerated approval of regenerative medicine products for serious or life threatening conditions. These became part of HR 5651 and FDA Reform Act of 2012 and S. 3187 the FDA Safety and Innoviation Act. Reimbursement policies for regenerative medicine prodcuts; comparative effectiveness research studies related to regenerative medicine products.
Filing targets: Agency for Healthcare Research & Quality (AHRQ), Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), Office of Science & Technology Policy (OSTP), SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2012 · first_quarter · Q1
Advocate for creation of federal coordinating entity for regenerative medicine. Met with NIH officals regarding same; Advocate for new/modified regulations regarding FDA approval of regenerative medicine products. Spoke with FDA officials about same. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011. Lobbied Congress to have provisions inserted in PDUFA reauthorization Energy & Commerce Committee draft legislation.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE
CITY OF NORFOLK VIRGINIA via HOLLAND & KNIGHT LLP
2011 · fourth_quarter · Q4
Issues related to post office closures.
Filing targets: Army, Dept of (Corps of Engineers), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2011 · fourth_quarter · Q4
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with FDA officials about same. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
CITY OF NORFOLK VIRGINIA via HOLLAND & KNIGHT LLP
2011 · third_quarter · Q3
Issues related to post office closures.
Filing targets: Federal Transit Administration (FTA), HOUSE OF REPRESENTATIVES, SENATE
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2011 · third_quarter · Q3
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Work with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
NATIONAL FISHERIES INSTITUTE via HOLLAND & KNIGHT LLP
2011 · second_quarter · Q2
Issues pertaining to implementation of Public Law 111-353, The FDA Food Safety Modernization Act; issues pertaining to federal nutrition advice relating to seafood.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE, White House Office
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2011 · second_quarter · Q2
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards.
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2011 · first_quarter · Q1
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Advocate for new/modified regulations re: FDA aprroval of regenerative medicine products. Met with NIST to explore collaborations re: manfacturing standards; Draft legislation to support regenerative medicine research
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2010 · fourth_quarter · Q4
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Lobby in support of HR 6173. Advocate for new/modified regulations re: aprroval of regenerative medicine products. The Regenerative Medicine Promotion Act of 2010. Met with NIST to explore collaborations re: product standards
ALLIANCE FOR REGENERATIVE MEDICINE via HOLLAND & KNIGHT LLP
2010 · third_quarter · Q3
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards for regenerative medicine. Support language in HR 2112 "Consolidated & Further Continuing Appropriations Act, 2012"
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards for regenerative medicine.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST officials on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Lobbied in support of HR 1862, The Regenerative Medicine Promotion Act of 2011.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Met with NIST officials on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST on standards for reginerative medicine products. Advocate for assessment of federal regenerative medicine activities. Draft legislation to support regenerative medicine research and development.
Advocate for funding for regenerative medicine companies and researchers in universities; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA. Advocate for funding for NIST to develop manufacturing standards.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for new regulations re: approval of regenerative medicine products. Advocate for funding for the FDA. Work with NIST on standards for reginerative medicine products.
Advocate for funding for regenerative medicine companies; Advocate for NIH funding for regenerative medicine research. Advocate for funding for the FDA.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institute of Standards & Technology (NIST), Natl Institutes of Health (NIH), SENATE
Advocate for funding for regenerative medicine companies; NIH funding for regenerative medicine research; funding for FDA to perform regulatory research and creation of federal coordinating entity for regenerative medicine. Draft and lobby in support of legislation that contains these provisions. Advocate for new/modified regulations re: aprroval of regenerative medicine products
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Natl Institutes of Health (NIH), SENATE